Warning: main(/home/corante/public_html/pipeline/includes/header.html) [function.main]: failed to open stream: No such file or directory in /home/corante/public_html/pipeline/archives/cat_index.php on line 1

Warning: main(/home/corante/public_html/pipeline/includes/header.html) [function.main]: failed to open stream: No such file or directory in /home/corante/public_html/pipeline/archives/cat_index.php on line 1

Warning: main() [function.include]: Failed opening '/home/corante/public_html/pipeline/includes/header.html' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/corante/public_html/pipeline/archives/cat_index.php on line 1
About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com

Chemistry and Pharma Blogs:
Pharmalot
Org Prep Daily
On Pharma
One in Ten Thousand
Away From the Bench
QDIS Blog
Chemical Musings
In Vivo Blog
The Chemblog
Molecule of the Day
Kinase Pro
Drugs and Poisons
Jungfreudlich
Chembark
Social Detritus
Pharmagossip
Whistling in the Wind
Organometallic Current
Great Molecular Crapshoot
Post Doc Ergo Propter Doc
A Chemist's Lab Notebook
The Curious Wavefunction Totally Synthetic
Pharma's Cutting Edge
The F- Blog
Synthetic Environment
Atom Pusher
Chemistry World Blog
Carbon-Based Curiosities
Eye on FDA
Hdreioplus
Closeted Chemistry
Chemical Forums
Curly Arrow
Power of Goo
Carbon Tet
Totally Medicinal
Sceptical Chymist
Lamentations on Chemistry
PeterMR
Mining Drugs
Regulatory Affairs of the Heart
Making Graphite Work
Liquid Carbon
Half-Decent Pharma Blog


Science Blogs and News:
The Loom
Uncertain Principles
The Crimson Canary
Fierce Biotech
Blogs for Industry
The Futile Cycle
Omics! Omics!
Young Female Scientist
Notional Slurry
Life of a Lab Rat
TP With Page Numbers
Nobel Intent
SciTech Daily
Is This Thing On?
Science Blog
Eastern Blot
Oncology Updates
FuturePundit
Flags and Lollipops
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Daily Biomed
Voyage to Arcturus
Adventures in Ethics and Science
Terra Sigillata
Transterrestrial Musings
The Mass Spectrometry Blog
Nodal Point
Slashdot Science
A Scientist's Life
Living the Scientific Life
John Johnson
Humans in Science
Tobias Sing's Bioinformatics Blog
Speculist
Science, Shrimp and Grits
Biopeer
Cosmic Variance
The Capsule
Zeroth Order Approximation
Science Library Blog
Biology News Net


Medical Blogs
MedPundit
Med Tech Sentinel
DB's Medical Rants
Dr. Charles
RangelMD
GruntDoc
The Health Care Blog
Cut to Cure
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Asymmetrical Information
Belmont Club
Man Without Qualities
Belgravia Dispatch
Mickey Kaus
Colby Cosh
Progressive Reaction
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night

In the Pipeline

Category Index
"Me Too" Drugs
Now Your Liver Doesn't Have to Make It For You
How Many PPIs Does the World Need?
Bad Luck For Novartis - And For Diabetics
Godzilla vs. Mothra? Relman vs. Epstein!
By a Nose in a Head to Head
No Clear Winners
Gritting Our Teeth
An Economist Who Gets It
Alex Tabarrok on Me-Too Drugs
Blurry Copies
The Last Word (For A While) On Me-Too Drugs
Me Too, Part Two
Clinical Trials And What to Do With Them
Hypertension and Marketing
Merck and Its Competition
Our Buddies at the FDA
Adam Smith Goes Pharmaceutical
Innovation and Its Discontents
Claritin and Clarinex

Academia (vs. Industry)
Lowe's Law of Diurnal Distribution
Getting To Lyrica
Scrape Off Some Attitude
Ugly, But Useful
Drugs From Where?
The Doctorate and Its Discontents
Naked Synthesis
What Can Academia Do?
Problems and Solutions
Peter Kim, So Far
Not On the Same Page
University of Drug Discovery?
The Great Divide
Mutual Suspicions
Differences Between Academia and Industry, Pt. 4
Sneaking Out for an Interview
Getting A Job
More on Question Four
Getting a Faster PhD?
The Bones of the World
Don't Become A Scientist?
Like Moving Furniture Across a Tightrope
Gumming Up the Amyloid Works
The NIH in the Clinic
One More On Basic Research and the Clinic
A Real-World Can O' Worms
How Much Basic Research?
How It Really Works
Will the Uncommon Work for the Common Good?
Industry vs. Academia: The Mental Aspect
Stuart Schreiber on Stuart Schreiber
Differences Between Academia and Industry, Pt. 2
Differences Between Industry and Academia, Pt. 1
On the Money

Aging and Lifespan
Resveratrol in Mice
Why Buy, Anyway?
$720 Million Worth of Sirtuin Research
Breaking the Contract of Aging
More Sirtuins With More Effects
And Thee, O Time
Sir2 Surprise
Klotho: Sooner Than You Think?
Breathing and Aging
When Natural Selection's Through With You - Part II
After Natural Selection's Through With You

Alzheimer's Disease
Rember for Alzheimer's: Methylene Blue's Comeback
Bapineuzumab: Good For Anything or Not?
Patents Stopping an Alzheimer's Wonder Drug?
Another Alzheimer's Compound Goes Down
Protecting Amyloid's Parent?
Elan Tries Again
In Which I Hate A Wonder Drug
Alzheimer's: A Report From the Front
ApoE4: Test or Not?
Fast Plaques in a Slow Disease
Checking The Numbers on the Alzheimer's Test
Beta-Secretase: Not So Fast?
Failure: Not Your Friend, But Definitely Your Companion
How Good Is Aricept, Anyway?
A Trial Too Far
Gumming Up the Amyloid Works
Silent Mutations and Noisy Ones
Back on the Air
Alzheimer's Vaccine Refuses to Die
Sleeping Dragons
Maybe They Can Formulate It in Madelaines
Who Dares, Wins?
Modeling the Brain?

Analytical Chemistry
Start Small, Start Right
These Fragments I Have Shored Against My Ruins
Mass Spec on Mars
Floyd Landis: Could His Cortisone Treatments Exonerate Him?
Testosterone, Carbon Isotopes, and Floyd Landis
Doublets, Triplets, Whateverlets
Medicine Man

Animal Testing
Whose Guess Is Better?
The Animal Testing Hierarchy
Unacceptable
Less Than Zero
Worst Animal Model: Nominations Are Open
Formally Undecideable
Rats Rule, Right?
Ends, Means, Rats, and Dogs
Model Systems, From Inside and Out
Furry Judges, With Tails
What to Do When the Rats Die on You
Rats, For Fear of Worse
You'll Only Get Answers
Modeling the Brain?

Autism
Thimerosal. Again.
Thimerosal, Again
A Mechanism for Thimerosal
Here and There
Compare and Contrast
The Rate of Autism
Clearance Sale
Thimerosal - A Chemical Point
Thimerosal - a Chemical Point
Clearance Sale
A Quick Tour Through the Mudhole
More on Autism (And Mercury)
More on Autism and Mercury
A Quick Tour Through the Mudhole
Neurotoxins
Neurotoxins
Doing Justice to Thimerosal, And the Story
Doing Justice to Thimerosal, and the Story

Biological News
Receptors: Can't Live With 'Em, Can't Understand 'Em
Killing Proteins Wholesale
Empty As Can Be
Nanotech Stem Cells, Order Now!
RNA Interference: Even Trickier Than You Thought
Getting Real With Real Cells
Rainbows and Fishing Expeditions
Avandia: Going Under for the Third Time?
A Real Genetic Headscratcher
What We Don't Know About Enzymes
Checking The Numbers on the Alzheimer's Test
Let Us Now Turn To the Example of Yo' Mama
More Things Than Are Dreamt Of
Visfatin: Real Or Not?
It Went Up Instead of Down
Peptides as Texts
Neowater Replies
Nanotech Wonder Water?
Stem Cell Disaster
Grand Rounds Today, and Next Week
RNAi: The Awkward Age
Kinases and Their Komplications
The Vapor Trail I Referred To
It's a Bacterial Planet, You Know
There'd Better Not Be an Argon Receptor
All Bets Are Now Officially Off
A New Cancer Target - Maybe
Proteinocentrism
Gene Therapy Decisions

Birth of an Idea
Vial Thirty-Three, And More
Back on the Air
Vial Thirty-Three: Warp Drive
The Race Is On
Publish, Then Perish
The Horse Latitudes
Good News, Now That I Think About It!
Back To Life
Vial Thirty-Three: The Third Run
Vial Thirty-Three Rides Again
Vial Thirty-Three: One Up, One Down
Mid-day Update
Minute by Minute
Vial Number Thirty-Three
Cliff Diving
A Scientist's Resolutions
Report From What I Think is the Frontier
Experimental News
News Flash: I May Not Be a Fool
Data, At Last
Experimental Update
Experimental Update, For Those Who Care
Live The Stereotype!
The Consolations of Pure Research
Don't Talk To Yourself So Much
Mismatched Socks
A Little Ambiguity Would Be Welcome Right About Now
Dr. Lowe? I Have Your Hypothesis on Line Two
If This Doesn't Work, There's Only Reality To Fall Back On
Good News, Backing Slowly Through the Door?
Waiting for the Metaphorical Phone to Ring
Per Fits and Starts, Ad Astra
Here It Goes
Nature Stood Me Up
Close to the Vest
Close To the Vest
Experimental Update
In Case Anyone's Wondering
Back for More
Meanwhile, Back at the Chocolate Factory
The Nuts and Bolts of a New Idea
Measure Twice, Cut Once

Blink ›
Nature Doesn't Care: Latest in a Series
Vaccines by the Dozen
Follow Which Money Where?
An Experiment in Progress?
Alex Tabarrok on Me-Too Drugs

Blog Housekeeping
Back
Time Off
Happy Fourth of July
Leaving Comments: A Fix
Explaining It All
Quick Note
Anonymity?
Day Off
Commenting Issues
Back On the Air
Snow Day
Synthetic Prep of the Day: Chocolate Pecan Pie
Holiday Break
Bright Lights and Applause?
Blogroll Update
Meet the Blogger?
Not Necessarily So
Two Weeks Off
Real Life, Which Costs Real Money
But Enough About You
Blogroll Update
Linkage!
Back From DC
You Want Me to Just Talk? No Problem.
Comments on Comments
Blogroll Update
Back on the Air
Work At Home! It's Easy; It's Fun!
Holiday Schedule
Shameless Self-Promotion
Elsewhere
Watch This Space
Links and Such
Darn Photons
Here and There
A Friday Linkfest
Back on the Air
Travel
Linkorama
Missed One!
A Lengthy Day
Technical Difficulties
Blogroll Revamp
Various Updates
Comments Welcome - Really
Instead of Working
Procrastination Assistance
Outside Reading, and Plenty of It
And Another Thing. . .
Blogging About Science Blogging
Even More Worthwhile Stuff
Like, Er, Fine Wine. I Hope.
Summer Hours
Continued Slacking
Outside Reading
New Address
One Problem Solved, Anyway
A Technical Question
And Now A Word. . .
Schedule Update
Holiday Blogging
Stocking Stuffers, of a Sort
Now With The Great Taste of Fish
Comment Problems
Two Days Off (From This, Anyway)
No Coming Attractions Here
A Question For the Audience
Summer Hours
The Last Word on Taste
Categories
Welcome Back!
Catching Up
Here and There

Business and Markets
RNAi: Bubble or Not?
Genentech and Roche, Act Two
Roche Palo Alto: What's Going On?
Job Seekers: Genentech, GSK, and Elsewhere
GSK Layoffs: Yes, Again
Iloperidone: A Schizophrenia Drug Goes Down For the Last Time
Should Genentech Be a Part of Roche?
Vytorin: Another Round of Nasty Results
Sharing the Enlightenment
More on Outsourcing
Pfizer's Prospects: Just Ducky
Alli: "Underwhelming"
Suits vs. Lab Coats?
More On the GSK Layoffs
GSK: Money-Green Outside, Pink-Slip Inside
A Breath of Fresh Air from Fuji
Nullius in Verba
Awash in Yen
Cordaptive Q and A
Why Buy, Anyway?
$720 Million Worth of Sirtuin Research
Free Sushi in the Cafeteria!
A Solution, Courtesy of the MIT Faculty
Hits, Misses, and Some More Misses
How Many PPIs Does the World Need?
Drugs and Money
Laissez-Faire?
Cheap Happiness
Drugs and Money and How It Feels
Dollar, Drugs, and Advertising
Top of the Heap
Hearing Footsteps
Biogen's Not For Buying. For Now.
Med-Chem Layoffs, On the Front Page
More Belts Tighten
How You Doin'? How's Everybody Doin'?
Lights, Camera, Pharma!
Come On. Improve, Already.
Surveying the Exubera Crater
Biogen on the Block?
More Layoffs, And What They Might Mean
Hey, Graduates! Negotiate Hard, You Hear, Now?
Good News From the HR Department!
Have We Got A Deal For You!
Guess That Market
Oh, Come On
Ah, Rumors
Buying What You Can't Make? Or What?
Exubera Spirals Toward the Drainpipe
European Drugs, American Drugs
Knowing What You Know. . .
Alas, Dendreon
Outsourcing Blues?
Put Your Money Down
Layoffs - Again
Amgen: The Pythian Oracle Laughs Again
Buy! Sell! Shout! Moan!
Vaccines Everywhere
Vectibix Lurches A Bit
Schering-Plough Goes Shopping
Biotech's Net Loss?
A Good Day's Work
Good Sense Breaks Out, Film at Eleven?
BMY-SNY?
The Big Picture
Pfizer's Pfinances
Novo Nordisk Axes Med-Chem
ICOS In Pieces?
Pfizer's Sizing
Sell! (It's Not Just Me)
Help Wanted - I Hope
Chinese Med-Chem - In China, For Once
Hope, Springing Eternal And All That
You Can't Make Money If You Don't Get Paid
Blow The Trumpets
Up Periscope And Fire All Bow Tubes
Imclone, Drama Queen of Biotech
Tough Targets
Walking the Plank at Bristol-Myers Squibb
Merck: Unfigure-outable
The Great Plavix Disaster
Pfizer's Man at the Top
Pfizer Recalculates
The Sun Shines at Pfizer
Getting and Spending
J&J Shrinks Their Labs Again
Neurocrine's Choice
The Fur Continues to Fly
What's German For "Food Fight"?
Leadership Secrets of the Data Fudgers
Full Disclosure
Golden Parachute, Still Packed and Ready
Rioting for Unemployment
Can You Say "Uebernahmeangebot"?
Nitromed's Slow Decline
More on Outsourcing
J&J Shakes Things Up
Forecast: Rain, Eventually
Imclone Revisited
The Tar Pit Beckons
James Cramer, Biocryst, and You
Human Genome Science Hits the Wall
Where Do the Good Ones Go?
The Check Shows Up in the Mail. Really.
Pfizer Opens Their Wallet - Again
You Figure It Out
Public Utility, You Say?
Punching the Clock at Merck
What Ails the Germans?
The Globalization of Med-Chem
Drug versus Stock
Waiting for the FDA
Glaxo v. Pfizer: Sales Force Stand-Down?
Pfizer's Prospects
Maybe They Should Fire Them All?
Optioning the Drug Portfolio
Don't Ask; Just Trade
Let's See What the Sharks Think of These Steaks!
Could I Have a Side Order of Risk With That?
Public Utility, You Say?
How Bad Are the Cox-2 Inhibitors, Anyway?
A Day With All the Bark Left On It
Rank and Yank?
Measure for Mismeasure
Around and About
Another Shot Across the Bow
Vox Populi
As Goes ASCO. . .
A Capacious Rat-Hole Indeed
Deferred Gratification Is Better Than None At All
Yahoots
Foaming Up Over the Edge
Bulking Up
Thou Hast It Now. . .
Play It Again
Tasty New Recipes for the Root of All Evil
Quis custodiet ipsos custodes?
Pravachol vs. Lipitor Update
Mismatched Socks
Ignorance Was Bliss
I will do such things - What they are yet I know not. . .
Allons Pharmas de la Patrie!
. . .Your Huddled Pharmas Yearning to Breath Free
Ah, Marketing
Mismeasure for Mismeasure
Measure for Measure
What Sort of Number Did You Have in Mind?
O Brave New Market, That Has Such Medicines In It
Bad News at a Bad Hour of the Night
Caveat Lector
Muddying the Water For Fun and Profit
Back For Some More
Marketing Ueber Alles
By Any Other Name
The Apatosaurus. The Spruce Goose. The Pyramids
The Irish Elk. The Mongol Empire. And Other Things That Got Too Big to Work Well.
A Less-Than-Subtle Plan

Cancer
GSK Layoffs: Yes, Again
Vytorin: Another Round of Nasty Results
Auroral Activity
And You Thought Exubera Was A Disaster Before
Whose Guess Is Better?
Judah Folkman
Plants For Cancer?
Bacterial Infection: Better Or Worse Than Cancer?
Arsenic, Patents, and the World
The Current Cancer Long-Jump Record
Phase Zero?
Let A Thousand Flowers Bloom
Amgen: The Pythian Oracle Laughs Again
Awful, No Doubt. But Not As Awful as Before?
Vaccines Everywhere
Failure: Not Your Friend, But Definitely Your Companion
Vectibix Lurches A Bit
A Good Day's Work
Good Mistakes?
An Innocent Question
Reality, Here In This Little Dish
Sell! (It's Not Just Me)
Blow The Trumpets
Here and There
Imclone, Drama Queen of Biotech
Tell 'Em You Work On Something Else
Resistance Isn't Quite Futile
That Fount of Information We Call ASCO
Jungle Rot
New Frontiers in Self-Deception
Price Gouging or Not?
Gold and Lasers
What's It Worth to You?
Mice, Humans, and Cancer
Another Shot at Cancer
The Hard News on Cancer
Hype or Hope?
No Such Disease
Selectivity: One of Those Flexible Concepts
A Tale of Two Trials
Cancer Delusions
When the Alternative is Nothing
Biotech At Last, Eh?
That Has to Be Good, Right?
ASCO Fever
'Tis the Season
The Price of Desperation
Targretin's Troubles
Drug versus Stock
Still Not All That Easy
Springtime for Oncology
What We Are Pleased to Call State of the Art
Black Friday: One Damn Thing After Another
The Coming Oncology
Check, Please
Tarceva Targets
Clay Lies Still, But Blood's A Rover
Costs and Benefits, Risks and Rewards
Another Shot Across the Bow
Bungee Jumping with PPAR Drugs
It'll Cost You
Vox Populi
As Goes ASCO. . .
All the Myriad Ways
Deferred Gratification Is Better Than None At All
Yahoots
Foaming Up Over the Edge
A New Cancer Target - Maybe
Back on the Air
Pneumonia, of All Things
O Brave New Market, That Has Such Medicines In It
Not Even Funny
Genetic Optimism
The Wall Street Journal versus the FDA
Consequences of Aneuploidy
Aneuploidy, or What're A Few Chromosomes, More or Less?
HER-1 And HER-2, Too
Save Your Tears
A Few Words
Did He Say What They Thought He Said?
Now Is the Peptide of Our Discontent
Hype and Glory
More Imclone, More Food for Thought
A Certain Tension in the Air
Imclone in Progress

Cardiovascular Disease
Vytorin: Another Round of Nasty Results
Prasugrel: Come Back This Fall
Merck, Vioxx: Seventeen and Three
In Which I Hate A Wonder Drug
Cordaptive Q and A
Another Cholesterol Medication Goes Down (Or Does It)?
Whose Guess Is Better?
Vytorin Numbers
Vytorin: It's A Pity
Pfizer vs. the NEJM: A Legal Showdown
Off Target? Which Target Did You Mean?
A Look Under the Hood
Vytorin, Holed Under the Waterline
Renin, Wherefore Art Thou, Renin?
Rimonabant, Out In the Light
The Avandia Wars Continue
More Avandia, And More on Marketing
Avandia: Trouble or Not?
The HDL Compost Pile
AGI-1067: Dead or Alive?
Torcetrapib: The Foil-Lined Hat Perspective
Bigger And Greasier
Too Near the Sun?
The Torcetrapib Catastrophe
Pfizer's Sizing
Ah, the Heck With the Error Bars
Elsewhere
It Should Work. It Just Doesn't.
Plavix Plot Twists
Merck: Unfigure-outable
The Great Plavix Disaster
Pfizer Recalculates
More Statin Skirmishing
Vioxx: 18 Months to Trouble?
As Merck Caroms Off Another Tree
Merck and the Numbers
Merck's Latest Underwhelming Data
The New England Journal And Its PR Flacks
Merck, So Far
Nitromed's Slow Decline
The Big Statin Pillow Fight
NEJM vs. Its Contributors, Round Two
Merck versus the New England Journal
Does Celebrex Have A Future At All?
An Expensive Way Back for Celebrex
The New England Journal of Legal Immunity?
Selectivity: One of Those Flexible Concepts
Merck on Trial
Where's the Combo?
A Drug's Target, Finally
COX-2 Aftermath
Waiting for the FDA
Boarding Up the Windows
The FDA Weighs In
Let's See What the Sharks Think of These Steaks!
Cox-2 Confusion
How Bad Are the Cox-2 Inhibitors, Anyway?
More on Merck
A Day With All the Bark Left On It
The Last Word (For A While) On Me-Too Drugs
Me Too, Part Two
Clinical Trials And What to Do With Them
Pravachol vs. Lipitor Update
Ignorance Was Bliss
Ezetimibe, The Press, and More
The Beginning? It's Right Past the End. . .
Sic Transit Gloria Mundi
Trials of Trials
Cholesterol Lowering, One Way or Another

Chem/Bio Warfare
The Litvinenko Case: More On Polonium and Alpha Particles
Evil Thoughts of Evil Things
A Fire, And Its Flames
Osmium Tetroxide, Of All Things
Ricin Redux
More Ricin
Ricin
And While We're On the Subject - Mercury?
A Mystery Gas?
Chemical Warfare, Part Five: The Real World
Chemical Warfare, Part Four: More On Nerve Agents and Their Chemistry
Chemical Warfare, Part Three: How Nerve Agents Work
Chemical Warfare, Part Two: Lethal Agents (Other Than Nerve Gas)
Chemical Warfare, Part One: Introduction

Chemical News
An Impressive Nanolist of Nanocitations
Copper: A Gentleman's Disagreement
New Tricks With Glassware
DNA Forklifts, DNA Pliers
Le Dernier Cri
One For the Brave
Ertl Wins: Down With Witchcraft
All Sorts of Holes
Steve Ley, Azadirachtin, and Me (Very Much in That Order)
ACS Meetings
Calcium: A Backwater
Smell the Vibrations
Six Chem-Geek Questions
Hexacyclinol Rides Again
Hexacyclinol? Or Not?
Chem-Geek Alternate History
A New Route to Tamiflu?
More on Woodward
Archaeologists Announce Dirty Laundry Discovery
Why Total Synthesis?
Climbing Mountains

Clinical Trials
Rember for Alzheimer's: Methylene Blue's Comeback
Iloperidone: A Schizophrenia Drug Goes Down For the Last Time
Vytorin: Another Round of Nasty Results
Glaxo Asks the Eurocrats
Another Alzheimer's Compound Goes Down
Fun With Bacteria
And You Thought Exubera Was A Disaster Before
Another Cholesterol Medication Goes Down (Or Does It)?
Vytorin: It's A Pity
You Get What You Pay For?
Taranabant in Trouble?
Hits, Misses, and Some More Misses
Antidepressants: Depressing News or Not?
A Look Under the Hood
Vytorin, Holed Under the Waterline
Come On. Improve, Already.
Deactivation, After All
Rimonabant: Down to Earth
Rimonabant, Out In the Light
Phase Zero?
Pecunia Non Olet?
The Avandia Wars Continue
Knowing What You Know. . .
Avandia: Trouble or Not?
Deep Breaths
Vectibix Lurches A Bit
FDA Advisory Panels: Pay, No Play
AGI-1067: Dead or Alive?
Vertex, Hepatitis, and Gripping the Arms of Your Chair
Upside Down Activity
Torcetrapib: The Foil-Lined Hat Perspective
Too Near the Sun?
The Torcetrapib Catastrophe
It Should Work. It Just Doesn't.
A Spray-Painted Crystal Ball
Tough Targets
Tegenero, In Detail
Vioxx: 18 Months to Trouble?
Formally Undecideable
A Question For the Crowd
Access to Phase I Drugs: A Constitutional Right?
A Word to the Wise About TGN1412
TNG1412: Was There a Warning?
Update on TGN1412
No Immunity From Immunity
But His Name Lives On. . .
The FDA Loosens Its Tie
An Expensive Way Back for Celebrex
Rigel's Puzzling Failure
This Had Better Be Good
By a Nose in a Head to Head
No Clear Winners
Muraglitazar's Turn
Gritting Our Teeth
Where's the Combo?
Still Not All That Easy
The NIH in the Clinic
One More On Basic Research and the Clinic
How It Really Works
Unburied
Me Too, Part Two
Clinical Trials And What to Do With Them
Fast, Cheap, and Sometimes Even Good
Primum Non Nocere, Eh?
The Journals Fight Back
Your One-Stop Clinical Data Superstore?
Cue the Music
Pravachol vs. Lipitor Update
Ignorance Was Bliss
More From the Me-Too Front
Putting A Price on Proving It
Here and There
Trials of Trials
Statins and Multiple Sclerosis
Muddying the Water For Fun and Profit
Save Your Tears

Closing Time
Med-Chem Layoffs, On the Front Page
Massachusetts Moving
A Post I've Been Looking Forward to For Months
Layoffs - Again
More Help Wanted?
Have We Got a Job For You!
A Break, Whether I Felt Like It Or Not
Open For Business
Ghost Town
Out With the Old
Cleans Down to What Should Be the Shine
Hi, My Name Is [...]
The Paper Mountain
Vial Thirty-Three: Warp Drive
Where Do All The Chemicals Go?
The Race Is On

Current Events
More Pfizer Layoffs?
Nullius in Verba
Judah Folkman
Ah, Politics
Unnatural, And Proud Of It
Ertl Wins: Down With Witchcraft
Nobel Chemistry Odds
Nobel Season
The Choir Hears It Again
Pour Encourager Les Autres
Access To Science
Time To Conduct Some Business
Layoffs - Again
Hedgehogs in Stockholm
F. A. Cotton, 1930-2007
CMPI Conference: Critical Path
CMPI Conference: Lunch With the FDA
CMPI Conference: Panel on the Politics of Drug Evaluation
CMPI Conference: Panel on Media Coverage
That Smell
And The Winner Is. . .
Injustice
The Litvinenko Case: More On Polonium and Alpha Particles
Polonium Poisoning
Help Wanted - I Hope
Here and There
Floyd Landis: Could His Cortisone Treatments Exonerate Him?
Airplanes and Chemicals
Testosterone, Carbon Isotopes, and Floyd Landis
Explosion News
Poor Put-Upon Intelligent Design
The Dover Decision Comes Down
Merck Update
Merck, Finally
Intelligent Design, Molecule By Molecule
The Dover Decision
Merck Off the Mat
Metathesis Nobel!
A Piece of the Action
Okay, One More Merck Point
No More Merck For A Couple of Days
Judgement Day
Welcome to the World, I Hope
Strangers on a Train
Special Off-Topic Weekend Irrelevancy
Actually, It's Everything Else That's Off-Topic
Happy Fourth of July
Osmium Tetroxide, Of All Things
And Another Thing. . .

Diabetes and Obesity
Metabolic Hope Springs Eternal
All The Fat Cells You'll Ever Have - Sort Of
Alli: "Underwhelming"
Merck Bails on Natural Products
Why Buy, Anyway?
Exubera, Safety, and No Guarantees
And You Thought Exubera Was A Disaster Before
Whose Guess Is Better?
Taranabant in Trouble?
Off Target? Which Target Did You Mean?
More On Merck and Taranabant
What You Become Known For
Eat It, Breath It, Soak in It?
Avandia: Going Under for the Third Time?
Bad Luck For Novartis - And For Diabetics
Depressing Figures for Acomplia
Surveying the Exubera Crater
More Things Than Are Dreamt Of
Buying What You Can't Make? Or What?
Exubera Spirals Toward the Drainpipe
Deactivation, After All
Visfatin: Real Or Not?
Right Down the Alli
Rimonabant: Down to Earth
Rimonabant, Out In the Light
The Avandia Wars Continue
More Avandia, And More on Marketing
Avandia: Trouble or Not?
Exubera: This Time With Feeling
Rimonabant, Slowly
You Can't Make Money If You Don't Get Paid
Up Periscope And Fire All Bow Tubes
The Inscrutable French
Neuropeptide Y Dies, But It Never Surrenders
Tell 'Em You Work On Something Else
Rimonabant Arrives
What's French for "Trust Us"?
Rimonabant Bangs Into. . .Something
Pfizer Takes a Deep Breath
Ghrelin and Obestatin
Pargluva Goes Down?
This Had Better Be Good
Waiting for Pargluva
Muraglitazar's Turn
Gritting Our Teeth
Symlin, At Last
Worries about Rimonabant?
Bungee Jumping with PPAR Drugs
Why Own the Car, When You Can Own the Road?
Ah, Marketing
Of All Sad Words. . .
Fighting City Hall
A Treadmill Pill?
Enzymes, Right and Wrong

Drug Assays
Receptors: Can't Live With 'Em, Can't Understand 'Em
Sharing the Enlightenment
Oops
The Miracle Solvent
Whose Guess Is Better?
Start Small, Start Right